A major international study led by researchers at University College London has found that semaglutide, the active ingredient ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

As the name suggests, peptide stacking involves combining multiple amino acid-based supplements to amplify their effects, ...

A groundbreaking study has compared the three top weight loss medications on the market, which has produced some surprising ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy can help people with excess weight and obesity lose ...

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...

The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...